Pre-made Lebrikizumab biosimilar ( Whole mAb, anti-IL13 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-299
Anti-IL13 therapeutic antibody (Pre-made Lebrikizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lebrikizumab (INN) is a humanized monoclonal antibody and an experimental immunosuppressive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. The drug was created by Tanox under the name TNX-650, and a phase I clinical trial for refractory Hodgkin's lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a Phase II clinical trial for the treatment of asthma.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL13 therapeutic antibody (Pre-made Lebrikizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||4i77:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox|
|Conditions Active||Atopic dermatitis|
|Conditions Discontinued||Asthma;Chronic obstructive pulmonary disease;Hodgkin's disease;Idiopathic pulmonary fibrosis|